Charles Riv Labs Intl Inc Stock Price, News & Analysis

Charles River Laboratories (NYSE: CRL) updated investors on a Board-led strategic review and announced actions to sharpen its portfolio, boost efficiency, and prioritize disciplined capital deployment.

Key moves: targeted sales of underperforming or non-core businesses representing approximately 7% of estimated 2025 revenue; projected non-GAAP EPS accretion of at least $0.30 annually from divestitures; cumulative restructuring savings of about $225 million annualized in 2026 plus incremental $70 million net cost savings; and a new $1.0 billion share repurchase authorization (the company repurchased $450.7 million since August 2024). Management will provide a fuller update at an Investor Day in 2026.

Charles River Laboratories (NYSE: CRL) reported Q3 2025 revenue of $1.00 billion, down 0.5% year-over-year, with organic revenue down 1.6%. GAAP net income available to common shareholders was $54.4 million or $1.10 GAAP EPS, versus $1.33 a year ago. Non-GAAP net income was $120.3 million and $2.43 non-GAAP EPS, declines of 10.0% and 6.2% respectively. Segment highlights: RMS revenue +7.9%, DSA revenue $600.7 million (-2.3%), Manufacturing revenue $190.7 million (-3.1%).

The company updated 2025 guidance: non-GAAP EPS $10.10–$10.30 and reported revenue change of (1.5)%–(0.5)%, and cited venture investment losses of $0.50 in full-year guidance. A live webcast is scheduled for November 5, 2025 at 9:00 a.m. ET.

Charles River (NYSE: CRL) and The Francis Crick Institute announced a collaboration on Antibody-Drug Conjugate (ADC) discovery and development on October 22, 2025. The agreement creates an integrated, end-to-end workflow spanning antibody discovery, conjugation, in vitro profiling, and preclinical studies, jointly managed to shorten timelines and improve efficiency.

The collaboration will use phage display libraries for high-affinity, target-specific antibodies and Charles River’s Retrogenix in vitro profiling platform to assess off-target interactions and enhance early safety evaluation.

Charles River (NYSE:CRL) announced a strategic collaboration with X-Chem on October 20, 2025 to expand hit identification capabilities by offering clients access to X-Chem’s DNA-encoded library (DEL) platform, which comprises a proprietary library of over 15 billion compounds. The partnership pairs Charles River’s protein production, assay development, and hit ID expertise with X-Chem’s DEL screening and data analysis to create an end-to-end workflow from hit identification to Hit-to-Lead optimization.

The collaboration is positioned to provide scalable, data-driven hit-finding options for biotech and pharma discovery programs and to broaden access to DEL screening through Charles River’s services.

Charles River (NYSE: CRL) announced a global Scientific Advisory Board, led by Dr. Namandjé N. Bumpus, to accelerate adoption of New Approach Methodologies (NAMs) for non-clinical safety and efficacy testing, aiming to reduce animal use.

The interdisciplinary board will embed in vitro, in silico, and in chemico methods across therapeutic, preventive, and chemical testing and support regulatory acceptance and commercial deployment. Examples cited include Endosafe Trillium, in vitro skin sensitization assays, virtual control groups, Logica, and NGS services.

Charles River Laboratories (NYSE: CRL) will release its third-quarter 2025 financial results on Wednesday, November 5, 2025 before the market opens. A conference call to discuss the results is scheduled the same day at 9:00 a.m. ET. Investors can listen to a live webcast and access a replay via the company's Investor Relations website at ir.criver.com.

Charles River (NYSE: CRL) and Toxys announced a collaboration on October 8, 2025 to offer Charles River clients access to ReproTracker, a human stem cell–based in vitro assay for rapid identification of developmental toxicity hazards. The assay complements traditional DART methods, can quantitatively predict teratogenic potential, and may serve as an early-phase screening platform or animal-free alternative for pharmaceuticals, agrochemicals and industrial chemicals.

The collaboration is positioned under Charles River’s Alternative Methods Advancement Project™ (AMAP™) and reinforces use of New Approach Methodologies (NAMs) and the 3Rs while leveraging Charles River’s DART services and historical control database.

Charles River Laboratories (NYSE: CRL) announced that CFO Flavia H. Pease will resign effective September 29, 2025, to pursue another opportunity. Michael G. Knell, current Corporate Senior Vice President and Chief Accounting Officer, has been appointed as interim CFO while the company conducts a comprehensive search for a permanent replacement.

The company has reaffirmed its 2025 financial guidance for revenue and non-GAAP earnings per share, which was previously provided on August 6, 2025, supported by current third-quarter performance outlook. CEO James C. Foster expressed confidence in Knell's ability to lead the finance organization during the transition period, citing his valuable experience since joining the company in 2017.

Charles River Laboratories (NYSE:CRL) has announced two strategic collaborations to advance oncology research and development through its contract development and manufacturing organization (CDMO). The company has formed an alliance with the Parker Institute for Cancer Immunotherapy (PICI), providing PICI network members access to Charles River's preclinical drug discovery and development services.

Additionally, Charles River will support Children's Hospital Los Angeles (CHLA) in manufacturing materials for a Phase I Clinical Trial, leveraging CHLA's $6 million award from the California Institute for Regenerative Medicine. The company's expanded cell and gene therapy portfolio offers comprehensive "concept-to-cure" advanced therapies solutions, focusing on plasmid DNA, viral vector, and cell therapy services.